Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine

Puntos clave

• The aim is to analyze immune correlates related to the mRNA-1283 vaccine's efficacy against COVID-19 variants.
• Conducted a randomized trial assessing immune responses to the mRNA-1283 vaccine.
• Evaluated neutralizing antibody (nAb) levels against COVID-19 variants.
• Correlated nAb levels with protection outcomes in vaccinated individuals.
• nAb levels against variants were significantly associated with stronger protection from COVID-19 (p<0.001).
• Protection was notably stronger for variants similar to circulating strains.
• Findings underscore the importance of nAb levels in vaccine effectiveness.